Business Context and Reporting Period
This Form 8-K filing by Sacks Parente Golf, Inc. (trading as Newton Golf Company, Inc., ticker: SPGC) reports on events occurring between December 11, 2024, and December 13, 2024. The filing details the entry into a material definitive agreement for a public equity offering and the subsequent closing of that offering.
Key Financial Metrics and Transaction Details
- Transaction Type: Public offering of Common Units and Pre-Funded Units.
- Units Sold: 7,000,000 Common Units (comprising 2,480,000 Common Units and 4,520,000 Pre-Funded Units).
- Offering Price: $1.20 per Common Unit; $1.199 per Pre-Funded Unit.
- Gross Proceeds: Approximately $8,400,000.
- Underwriting Discount: 7% of the public offering price.
- Expense Allowance: 1% of gross proceeds.
- Legal Fee Reimbursement: Up to $100,000 for the underwriter's counsel.
- Over-Allotment Option: Underwriter granted a 45-day option to purchase up to 15% additional securities.
Material Changes and Warrant Terms
The offering introduces significant dilutive features subject to stockholder approval ("Warrant Stockholder Approval"). Key terms include:
- Warrant Structure: Each unit includes Series A Warrants (5-year term) and Series B Warrants (2.5-year term) with an initial exercise price of $2.40 (200% of the offering price).
- Reset Provisions: Series A Warrants include a "Reverse Split Reset" and a "Dilutive Adjustment" if the company issues stock below the exercise price. Both are subject to a "Floor Price" (initially 50% of the Nasdaq Minimum Price).
- Cashless Exercise: Series B Warrants allow for a cashless exercise option yielding 2.0 shares for every 1 share issuable upon cash exercise.
- Exercisability: Warrants cannot be exercised until stockholder approval is obtained. The company must hold a stockholders meeting within 60 days of closing to approve warrant terms.
- Lock-Up: Company executives and directors are restricted from selling shares for 90 days post-offering without underwriter consent.
Guidance, Outlook, and Risks
The filing does not provide specific financial guidance, revenue outlook, or management commentary regarding future operational performance. The primary risks and contingencies identified are:
- Dilution Risk: The complex warrant terms, including reset mechanisms and cashless exercise options, pose significant potential dilution to existing shareholders.
- Regulatory Contingency: Full exercisability of the warrants and removal of certain price floors are contingent upon stockholder approval, which must be sought within 60 days of the offering closing.
- Liquidity: The transaction provides immediate gross proceeds of approximately $8.4 million, subject to deductions for fees and expenses.
Investor Verification Checklist
- Verify the exact net proceeds after deducting the 7% underwriting discount, 1% expense allowance, and legal reimbursements.
- Confirm the date and outcome of the upcoming stockholders meeting required to approve warrant exercisability and adjustments.
- Monitor the Nasdaq Minimum Price to understand the "Floor Price" impact on potential warrant resets.
- Review the full text of the Underwriting Agreement (Exhibit 1.1) and Warrant forms (Exhibits 4.1 and 4.2) for specific conditions on the "Dilutive Adjustment."
- Check for any exercise of the 15% over-allotment option within the 45-day window.